UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

Precision oncology in metastatic colorectal cancer - from biology to medicine

Nature reviews. Clinical oncology, 2021-08, Vol.18 (8), p.506-525

2021

Volltextzugriff (PDF)

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical cancer research, 2019-05, Vol.25 (10), p.3046-3053

2019

Volltextzugriff (PDF)

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2014-07, Vol.384 (9940), p.319-328

2014

Volltextzugriff (PDF)

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (6), p.2643-2648

2007

Volltextzugriff (PDF)

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Journal of clinical oncology, 2008-09, Vol.26 (25), p.4217-4219

2008

Volltextzugriff (PDF)

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

Expert review of anticancer therapy, 2020-05, Vol.20 (5), p.333-341

2020

Volltextzugriff (PDF)

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1619-1625

2008

Volltextzugriff (PDF)

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Journal of clinical oncology, 2005-12, Vol.23 (35), p.8942-8949

2005

Volltextzugriff (PDF)

Integrating liquid biopsies into the management of cancer

Nature reviews. Clinical oncology, 2017-09, Vol.14 (9), p.531-548

2017

Volltextzugriff (PDF)

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4124-TPS4124

2020

Volltextzugriff (PDF)

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5335-5343

2008

Volltextzugriff (PDF)

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1360-1377

2000

Volltextzugriff (PDF)

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3594-3594

2018

Volltextzugriff (PDF)

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Journal of clinical oncology, 2016-03, Vol.34 (7), p.e54-e56

2016

Volltextzugriff (PDF)

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3508-3508

2015

Volltextzugriff (PDF)

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

Nature medicine, 2022-08, Vol.28 (8), p.1640-1645

2022

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of clinical oncology, 2024-01, Vol.42 (1), p.47

2024

Volltextzugriff (PDF)

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3636-3636

2013

Volltextzugriff (PDF)

Time course of regorafenib-associated adverse events in the phase III CORRECT study

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.467-467

2013

Volltextzugriff (PDF)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Clinical cancer research, 2022-04, Vol.28 (7), p.1302-1312

2022

Volltextzugriff (PDF)

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Cancer, 2016-02, Vol.122 (4), p.574-581

2016

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaColorectal Neoplasms - Drug Therapy

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(200)

Publikationsform

Artikel
(216)

Sprache

Englisch
(216)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Humans
(67)
Science & Technology
(67)
Life Sciences & Biomedicine
(61)
Oncology
(44)
Biological And Medical Sciences
(34)
Male
(34)
Female
(33)
Medical Sciences
(33)
Middle Aged
(24)
Adult
(23)
Tumors
(21)
Aged
(18)
Hematology
(11)
Treatment Outcome
(10)
Chemotherapy
(9)
Disease-Free Survival
(9)
Pharmacology. Drug Treatments
(9)
Aged, 80 And Over
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Animals
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Precision oncology in metastatic colorectal cancer - from biology to medicine

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Integrating liquid biopsies into the management of cancer

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Time course of regorafenib-associated adverse events in the phase III CORRECT study

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Aktive Filter

Suchergebnisse filtern